硅谷初创公司成功融资9100万美元，志在（研制纯素原料）取代化妆品和小熊软糖中的胶原蛋白、明胶

原文：https://vegnews.com/2020/7/silicon-valley-startup-raises-91-million-to-replace-collagen-and-gelatin-in-cosmetics-gummy-bears

注：译文谨供参考。

SILICON VALLEY STARTUP RAISES $91 MILLION TO REPLACE COLLAGEN AND GELATIN IN COSMETICS, GUMMY BEARS

硅谷初创公司成功融资9100万美元，志在（研制纯素原料）取代化妆品和小熊软糖中的胶原蛋白、明胶

Biodesign startup Geltor is working to create animal-free ingredient solutions across the cosmetic, food, and nutrition industries to help manufacturers create sustainable, cruelty-free consumer products.

（美国）生物设计初创公司Geltor正在努力为化妆品、食品和营养行业创建无动物的原料解决方案，以帮助制造商们打造可持续、无残酷性的消费产品。

by ANNA STAROSTINETSKAYA

作者：ANNA STAROSTINETSKAYA

JULY 27, 2020

2020年7月27日

Today, Silicon Valley startup Geltor announced it has raised a $91.3 million Series B investment round to help accelerate its mission to replace animal-derived proteins, such as collagen and gelatin, with vegan ingredients in a variety of consumer packaged goods. Founded in 2015 by Princeton University graduates Alex Lorestani, PhD and Nick Ouzounov, PhD, Geltor develops vegan proteins that replace their animal-derived counterparts—such as collagen (a component of gelatin)—for the skincare, food, and dietary supplement industry through a proprietary process that relies on plant-based fermentation. The company will use the new funding to fuel the expansion of its “Ingredients-as-a-Service” platform on a global scale.

硅谷初创公司Geltor今天宣布已在B轮融资中筹集了9130万美元，以助力加快实现其这一使命：精心研制各种（高性能的）纯素原料，用于取代各式各样的快速消费品（CPG）中的胶原蛋白和明胶等动物源性蛋白质。美国普林斯顿大学（Princeton University）的两名博士毕业生亚历克斯·洛雷斯塔尼（Alex Lorestani）和尼克·奥佐诺夫（Nick Ouzounov）于2015年共同创立了Geltor公司。通过采用依靠植物性发酵的专有工艺，该公司为护肤、食品和膳食补充剂行业开发各种纯素蛋白质，用于逐一取代对应的动物源性蛋白质，例如胶原蛋白（明胶的一种成分）、等等。Geltor公司将利用新筹得的资金在全球范围内推动扩大其“原料即服务”（“Ingredients-as-a-Service”）平台。

“Our goal is to make it ridiculously easy for iconic brands to build sustainable products. This next stage of growth will allow Geltor to meet the moment our world is facing, as businesses recognize the urgent need to transition to a sustainable protein supply chain,” Lorestani said. “We’re grateful to have investors who see Geltor as an index of this important shift to a system powered by fermentation and plant-based platforms like ours. As a scientist, I’m convinced that the highest-impact action I can take to support human and planetary health is making our Ingredients-as-a-Service platform better every single day.”

“我们的目的是使各家标志性品牌都能非常容易地打造各种可持续产品。现在各企业认识到迫切需要过渡到可持续的蛋白质供应链，Geltor公司下一阶段的发展将可以有效应对我们世界正在面临的这一关键时刻，”洛雷斯塔尼说道。“在业界转向如同本公司这样的发酵和植物性平台所支撑的系统时，我们很感激拥有这些（高瞻远瞩的）投资者，他们将Geltor公司看作是这一重大转变的标志。在支持人类和地球的健康方面，我作为一名科学家，坚信自己能够发挥的最大作用就是，每天都不断改进我们的‘原料即服务’平台。”

Earlier this year, Geltor launched Elastapure—the first-ever 100-percent plant-based elastin ingredient—a key protein in skincare that stimulates cell growth and helps skin maintain its elasticity as it ages. The company also produces vegan collagens in two formulations, HumaColl21 and Collume, and signed a multi-million dollar agreement in 2019 with leading collagen manufacturer GELITA to commercialize the world’s first animal-free collagen.

Geltor公司在今年早些时候推出了Elastapure产品──首创100%植物性的弹性蛋白原料──弹性蛋白在护肤方面是一种重要蛋白质，能够刺激细胞生长并帮助皮肤在老化时保持弹性。Geltor公司还生产两种配方的纯素胶原蛋白产品HumaColl21和Collume，并在2019年与全球领先的胶原蛋白制造商嘉利达（GELITA）签署了一份价值数百万美元的协议，以商业化本公司生产的世界上首款无动物的胶原蛋白产品。

While the global industrial supply chain was heavily disrupted in the last year with the outbreak of African Swine Fever and COVID-19, Geltor was able to scale its technology platform by 100-fold, producing hundreds of new animal-free proteins that are resilient against disease-driven disruption. “We see huge market potential for Geltor’s protein platform across categories from cosmetics to food. We are excited by the speed and skill with which they are building out their capabilities,” said Costa Yiannoulis, Investment Director at CPT Capital which led Geltor’s Series B round. “Even more so, in light of the havoc wreaked by COVID-19 on protein supply chains globally, we believe Geltor is laying the foundations for the sustainable, resilient, protein supply chain of the future.”

尽管去年非洲猪瘟（ASF）和2019冠状病毒病（COVID-19）爆发导致全球产业供应链遭受重创，但是Geltor公司仍然能够将其技术平台扩大了100倍，生产数百种新的无动物蛋白质，能够有效抵御疾病引发的供应链中断。“Geltor公司的蛋白质平台涵盖了从化妆品到食品的多个产品类别，我们看到该蛋白质平台具有巨大的市场潜力。他们（Geltor公司）拓展自己能力的速度和技艺使我们感到很兴奋，”领投Geltor公司B轮融资的CPT Capital公司投资总监科斯塔·伊安诺里斯（Costa Yiannoulis）说道。“让我们更加激动的是，鉴于COVID-19疾病大流行对全球蛋白质供应链造成了严重破坏，我们认为Geltor公司正在为建立可持续、牢不可破的未来蛋白质供应链奠定基础。”